Immunocytochemistry/ Immunofluorescence: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of immersion fixed splenocytes. Primary antibody was used at a dilution of 10 ug/mL and ...read more
Immunohistochemistry: CD8 Antibody (53-6.7) [NBP1-49045] - Histopathological analysis of spinal cord in EAE mice. Representative spinal cord sections from wild-type (WT), Asic1-/- , and Asic2-/- mice at 45 days after ...read more
Flow Cytometry: CD8 Antibody (53-6.7) - BSA Free [NBP1-49045] - Analysis of isolated mouse splenic CD8+ T cells using CD8 antibody (53-6.7) [Allophycocyanin] (NBP1-49045APC). Image from verified customer review.
Immunohistochemistry-Frozen: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of mosue spleen sections. CD8+ lymphocytes are marked by brown labeling of the cell surface.
Immunohistochemistry-Frozen: CD8 Antibody (53-6.7) [NBP1-49045] - Analysis of CD8+ T cells in allogeneic skin grafted onto a mouse.
Flow Cytometry: CD8 Antibody (53-6.7) [NBP1-49045] - Analysis of fixed murine splenocytes by multiple staining.
This CD8 alpha antibody serves as an effective marker of cytotoxic T lymphocytes by binding to the CD8 co-receptor expressed on the cell surface of cytotoxic T cells, recognizing the topological domain of CD8 alpha. Because this CD8 antibody is made to the alpha chain it will recognize both the CD8 alpha - CD8 beta heterodimer, the most common form, as well as the CD8 alpha - CD8 alpha homodimer. The CD8A gene is also expressed in natural killer cells (NK cells), dendritic cells and cortical thymocytes making the CD8 alpha antibody a potential marker for these cells.
CD8 Antibody (53-6.7) was developed against mouse thymus or spleen.
Most thymocytes, T cell subset, some NK cells
Protein A or G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Each lot of this CD8a antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is <0.25 ug/10^6 cells in 100 uL volume. It is recommended that the reagent be titrated for optimal performance for each application. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation, in vivo and in vitro cell depletion, inhibition of CD8 T cell proliferation, blocking of cytotoxicity, and immunohistochemical staining of both acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections. Use in ICC/IF was reported in scientific literature. Use in Immunohistochemistry-Paraffin reported in scientific literature (PMID 24565643).
27 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read 3 Reviews rated 3.7 using NBP1-49045 in the following applications:
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.02% Sodium Azide
Protein A or G purified
Alternate Names for CD8 Antibody (53-6.7) - BSA Free
53-6.7 CD8 Alpha
53-6.7 CD8 Aplha
CD8 antigen, alpha polypeptide (p32)
Cytotoxic T cell marker
Cytotoxic T lymphocyte marker
Leu2 T-lymphocyte antigen
OKT8 T-cell antigen
T cell co-receptor
T cell marker
T8 T-cell antigen
T-cell antigen Leu2
T-cell surface glycoprotein CD8 alpha chain
T-lymphocyte differentiation antigen T8/Leu-2
CD8, also known as Leu-2 or T8 in human and Lyt2 or Lyt3 in mouse, is a cell surface glycoprotein belonging to the immunoglobulin supergene family (1, 2). CD8 is expressed on cytotoxic T-lymphocytes (T-cells), most thymocytes, between 35-45% of peripheral blood lymphocytes, and a population of natural killer (NK) cells (1, 2). The CD8 molecule consists of disulfide-linked alpha (alpha) and beta (beta) chains that present on T-cells as either CD8alphaalpha homodimers or CD8alphabeta heterodimers (1, 3). Both alpha and beta chains consist of a signaling sequence, an extracellular Ig-like domain, a membrane proximal stalk region, a transmembrane domain, and a cytoplasmic tail (3). Human CD8alpha is processed as 235 amino acids (aa) in length with a theoretical molecular weight of ~26 kDa, while mouse CD8alpha is 247 aa and has a theoretical molecular weight of 27.5 kDa (4, 5). Functionally, CD8 acts as an antigen coreceptor on cytotoxic T-cells and interacts with the major histocompatibility complex (MHC) class I molecules on antigen presenting cells (APCs), mediating cell-cell interactions within the immune system. Conversely, CD4 molecules interact with antigens presented on MHC class II molecules and are activated to become helper T-cells (TH) (1,2). Interestingly, thymocytes can transiently express both CD4 and CD8 during the maturation process (2). Furthermore, the cytoplasmic tail of CD8 has a Lck (lymphocyte-specific protein tyrosine kinase) binding domain where Lck interacts with CD8, initiating a phosphorylation cascade that activates transcription factors and promotes T-cell activation (6). More specifically, CD8alphabeta functions as a T-cell co-receptor, while CD8alphaalpha promotes T-cell survival and differentiation (7).
Given its role in the immune system, CD8-deficiency in T-cells is a hallmark of many diseases and pathologies (8-10). Specifically, CD8+ T-cell deficiency is prevalent in chronic autoimmune diseases including multiple sclerosis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, type 1 diabetes mellitus, and Graves' disease (8). Furthermore, cancers or chronic infection can lead to CD8 T-cell exhaustion as the continual antigen presentation and inflammatory signals eventually cause the CD8+ T-cells to lose functionality (9, 10). However, animal models and clinical studies have suggested that T-cells are capable of being reinvigorated using inhibitory receptor blockade resulting in better disease outcomes and these exhausted T-cells may be a potential therapeutic target (9, 10).
Alternative names for CD8 includes CD antigen: CD8a, CD8 antigen, alpha polypeptide (p32), CD8a molecule, CD8A, Leu2 T-lymphocyte antigen, LEU2, MAL, OKT8 T-cell antigen, p32, T cell co-receptor, T8 T-cell antigen, T-cell antigen Leu2, T-cell surface glycoprotein CD8 alpha chain, and T-lymphocyte differentiation antigen T8/Leu-2.
1. Littman D. R. (1987). The structure of the CD4 and CD8 genes. Annual review of immunology. https://doi.org/10.1146/annurev.iy.05.040187.003021
2. Naeim F. (2008). Chapter 2- Principles of Immunophenotyping. Hematopathology. https://doi.org/10.1016/B978-0-12-370607-2.00002-8.
3. Gao, G. F., & Jakobsen, B. K. (2000). Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunology today. https://doi.org/10.1016/s0167-5699(00)01750-3
4. UniProt (P01732)
5. UniProt (P01731)
6. Kappes D. J. (2007). CD4 and CD8: hogging all the Lck. Immunity. https://doi.org/10.1016/j.immuni.2007.11.002
7. Gangadharan, D., & Cheroutre, H. (2004). The CD8 isoform CD8alphaalpha is not a functional homologue of the TCR co-receptor CD8alphabeta. Current opinion in immunology. https://doi.org/10.1016/j.coi.2004.03.015
8. Pender M. P. (2012). CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune diseases. https://doi.org/10.1155/2012/189096
9. Kurachi M. (2019). CD8+ T cell exhaustion. Seminars in immunopathology. https://doi.org/10.1007/s00281-019-00744-5
10. Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018). CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual review of medicine. https://doi.org/10.1146/annurev-med-012017-043208
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Attempted IF with this primary antibody against CD8 at concentrations 1:500, 1:200, 1:100, 1:50, 1:20, and 1:10. At concentrations >1:100 we were able to see dim positivity for IHC with HRP, but we were never able to visualize CD8 cells with immunofluorescence using either Alexa 488 and Alexa 468 secondaries (both secondaries confirmed working against other rat primaries). Unfortunately we needed to costain against two other targets so IHC alone didn't work for our purposes. ***Novus Response: Thank you for reviewing our product. We are sorry to that that this antibody did not perform as expected. We have been in touch with the customer to resolve this issue according to our Product Guarantee and to the customer’s satisfaction.***
FAQs for CD8 Antibody (NBP1-49045). (Showing 1 - 1 of 1 FAQs).
Could you provide me with any suggestions for CD8 antibodies that work well with a CD4 antibody?
NBP1-28254, NBP1-28336, NBP1-28238, NBP1-49045 and NBP2-80658 have images of mostly Flow Cytometry analyses for CD4 and CD8. NB200-578 induces transplantation tolerance when used in conjunction with CD4 antibodies. I would suggest taking a look at these products to determine if they would be suitable for your experiments.
Is Monkeypox Still A Threat? By Jamshed Arslan, Pharm D, PhD Monkeypox is not deadly like its cousin, smallpox, nor is it as contagious as COVID-19. Yet, it continues to scare the world. In May 2022, a multinational outbreak of a cont... Read full blog post.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.